Literature DB >> 14624916

Gadolinium-enhanced MRI in the evaluation of minimally invasive treatments of the prostate: correlation with histopathologic findings.

Benjamin T Larson1, Joseph M Collins, Christian Huidobro, Alberto Corica, Santiago Vallejo, David G Bostwick.   

Abstract

OBJECTIVES: To explore the use of magnetic resonance imaging (MRI) with gadolinium enhancement as a noninvasive method to image the extent of ablation after minimally invasive treatment. Minimally invasive methods for ablating prostatic tissue have emerged as a viable option in the treatment of prostate disease. As these devices enter the mainstream of patient care, imaging methods that verify the exact location, extent, and pattern of the ablation are needed.
METHODS: Nineteen patients with prostate cancer were evaluated. All received some type of minimally invasive treatment, post-treatment gadolinium-enhanced MRI sequences, and radical retropubic prostatectomy for histopathologic evaluation. Visual comparisons of gadolinium defects and areas of coagulation necrosis as seen on histopathologic evaluation were made by us. Volumetric and two-dimensional area measurements of the ablation lesions were also compared for correlation between the MRI and histopathologic results.
RESULTS: Gadolinium-enhanced MRI could be matched to histopathologic findings by visual comparison in 17 of the 19 cases. Surgically distorted histopathologic specimens and a small periurethral lesion caused 2 patients to have MRI and histopathologic results that could not be matched. Complete volumetric measurements were available for 16 of the 19 patients and correlated strongly (r = 0.924). The two-dimensional area data for all patients also showed significant correlation (r = 0.886).
CONCLUSIONS: Correlation with histopathologic findings showed gadolinium-enhanced MRI to be useful for determining the location, pattern, and extent of necrosis caused within the prostate by minimally invasive techniques. Gadolinium-enhanced MRI gives the urologist a useful tool to evaluate the effectiveness of new minimally invasive therapies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14624916     DOI: 10.1016/s0090-4295(03)00586-7

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  8 in total

1.  Relationship between tumour growth rate and carbogen-based functional MRI for a chemically induced HCC in mice.

Authors:  C D Thomas; E Chenu; C Walczak; M-J Plessis; F Perin; A Volk
Journal:  MAGMA       Date:  2004-12-20       Impact factor: 2.310

2.  Magnetic resonance imaging correlated with the histopathological effect of Pd-bacteriopheophorbide (Tookad) photodynamic therapy on the normal canine prostate gland.

Authors:  Zheng Huang; Masoom A Haider; Susan Kraft; Qun Chen; Dominique Blanc; Brian C Wilson; Fred W Hetzel
Journal:  Lasers Surg Med       Date:  2006-08       Impact factor: 4.025

Review 3.  Role of imaging and biopsy to assess local recurrence after definitive treatment for prostate carcinoma (surgery, radiotherapy, cryotherapy, HIFU).

Authors:  Pasquale Martino; Vincenzo Scattoni; Andrea B Galosi; Paolo Consonni; Carlo Trombetta; Silvano Palazzo; Carmen Maccagnano; Giovanni Liguori; Massimo Valentino; Michele Battaglia; Libero Barozzi
Journal:  World J Urol       Date:  2011-05-08       Impact factor: 4.226

Review 4.  Image guidance for focal therapy of prostate cancer.

Authors:  U Lindner; N Lawrentschuk; J Trachtenberg
Journal:  World J Urol       Date:  2010-10-21       Impact factor: 4.226

Review 5.  Focal therapy in prostate cancer: modalities, findings and future considerations.

Authors:  Uri Lindner; John Trachtenberg; Nathan Lawrentschuk
Journal:  Nat Rev Urol       Date:  2010-09-14       Impact factor: 14.432

6.  Recent advances in magnetic resonance imaging of prostate cancer.

Authors:  Nathan Lawrentschuk; Uri Lindner
Journal:  F1000 Med Rep       Date:  2010-12-08

Review 7.  Early experience in MRI-guided therapies of prostate cancer: HIFU, laser and photodynamic treatment.

Authors:  M R Da Rosa; J Trachtenberg; R Chopra; M A Haider
Journal:  Cancer Imaging       Date:  2011-10-03       Impact factor: 3.909

8.  Transurethral convective water vapor as a treatment for lower urinary tract symptomatology due to benign prostatic hyperplasia using the Rezūm(®) system: evaluation of acute ablative capabilities in the human prostate.

Authors:  Christopher M Dixon; Edwin Rijo Cedano; Lance A Mynderse; Thayne R Larson
Journal:  Res Rep Urol       Date:  2015-01-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.